Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo's OTC Priority Shows In Launch Of Imodium Multi-Symptom Equivalent

Executive Summary

Perrigo is launching generic of J&J’s OTC Imodium Multi-Symptom Relief product for diarrhea and gas. An analyst estimates the product could generate $15m in annualized sales.


Related Content

Another Change At Perrigo Helm As Results Remain Turbulent
Perrigo's OTC Core Could Expand To Include National Brands
Smaller OTC Loperamide Packages Wait As Retailers Limit Purchase Amounts
Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts